Changes/additions to materials:
Since these materials were published on NPCi, NICE has issued guidance on the use of adalimumab▼ for treating adults with psoriasis. Generally, it recommends using adalimumab only in patients who have severe plaque psoriasis, where standard systemic psoriasis treatments have been tried or are unsuitable. See our blog for a brief summary.

There is no patient decision aid available for this therapeutic topic.